Four-Drug attack on blood cancer tested for frail patients
NCT ID NCT04009109
Summary
This study is testing a combination of four drugs (lenalidomide, ixazomib, dexamethasone, and daratumumab) for older adults or those too frail for a stem cell transplant who have newly diagnosed multiple myeloma. The goal is to see if adding more drugs during long-term 'maintenance' therapy can better control the cancer and keep it from progressing. Researchers will compare two different maintenance regimens to see which is more effective and tolerable.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOMA, MULTIPLE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Gibbs Cancer Center & Research Institute/Spartanburg Regional Healthcare
Spartanburg, South Carolina, 29303, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Northern Light Eastern Maine Medical Center
Bangor, Maine, 04401, United States
-
SUNY Upstate Medical Center
Syracuse, New York, 13210, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68152, United States
-
University of North Carolina
Chapel Hill, North Carolina, 27514, United States
Conditions
Explore the condition pages connected to this study.